CA-RSA
9.6.2021 15:02:14 CEST | Business Wire | Press release
RSA Security LLC ("RSA" or the "Company") today announced the transition of its Fraud & Risk Intelligence business into a new standalone company serving a worldwide customer and partner community.
The new organization, Outseer, is led by CEO Reed Taussig who joined the RSA Fraud & Risk Intelligence business in late 2020 and is a veteran of the fraud prevention and digital identity industry.
With this strategic transition defined by self-directed company management and a modern corporate identity, Outseer will continue to deliver all heritage products in a newly constituted portfolio:
- Outseer Fraud Manager™: (formerly RSA Adaptive Authentication) protects customers across all digital channels with risk-based account monitoring decisions
- Outseer 3-D Secure™: (formerly RSA Adaptive Authentication for eCommerce) the gold standard in card-not-present and digital payments authentication mapping to the latest EMV® 3-D Secure standard
- Outseer FraudAction™: (formerly RSA FraudAction) delivers rapid detection, takedown, and data insights related to phishing sites, rogue apps, and fraudulent social media pages
Together, these award-winning offerings serve as the benchmark for payments authentication, detecting account compromise fraud, and fraud investigations while upholding friction-free customer experiences for the world’s leading merchants, issuing banks, and payment providers.
Underlying the Outseer product portfolio are two deep investments in data and science:
- Outseer Global Data Network™: The industry’s first global consortium of verified fraud and transaction data
- Outseer Risk Engine™: Identity-centric risk graph delivering 95% fraud detection rates with an intervention rate of 5% or less
“Outseer is the culmination of decades of science-driven innovation in anti-fraud and payments authentication solutions,” Taussig said. “As the digital economy continues to deepen, the Outseer mission to liberate the world from transactional fraud is essential. Our role as a revenue enabler for the global economy will only strengthen as every digital business continues to scale.”
This move follows the COVID-19 pandemic which fueled unprecedented growth in digital commerce, compressing a decade of transformation into 12 months. Payment card schemes, issuing banks, and commerce providers have witnessed unprecedented fraudulent transactions and even orchestrated attacks in their payment networks.
To meet these new challenges, Outseer will continue to innovate their payments authentication offerings, mapping closely to the EMV® 3-D Secure 2.x payment standard and incorporating new technology integrations across the payments and commerce ecosystem.
“Outseer’s reason for being isn’t just focused on eliminating payments and account fraud,” Taussig said. “These fraudulent transactions are often the pretext for more sinister drug and human trafficking, terrorism, and other nefarious behavior. Outseer has the ability to help make the world a safer place.”
Founded in 1982, RSA has built a reputation over four decades of being a critical solution provider for security-sensitive customers and a leader of innovation that enables enterprises to address rapidly evolving risks and security threats. Today, RSA services 2 billion individual users and has 26 million identities under management, and more than 12,500 customers rely on RSA's software solutions to enable their digital transformation, address increasingly advanced cyber threats and adapt to more complex digital regulations.
RSA announced in 2020 that it had begun operating as an independent company via acquisition by Symphony Technology Group, valuing the company at $2.1 billion.
Related resources:
- Watch the Outseer introduction video
- Visit Outseer.com
- Request a demo of Outseer products
About Outseer
Outseer, an RSA company, empowers the digital economy to grow by authenticating billions of transactions annually. Our payment and account monitoring solutions increase revenue and reduce customer friction for card issuing banks, payment processors, and merchants worldwide. Leveraging 20 billion annual transactions from 6,000 global institutions contributing to the Outseer Data Network, our identity-based science delivers the highest fraud detection rates and lowest customer intervention in the industry. See what others can’t at outseer.com .
About RSA
RSA, a leader in cybersecurity and risk management solutions, provides organizations with technology to address challenges across security, risk management and fraud prevention in the digital era. RSA solutions are designed to effectively detect and respond to advanced attacks; manage user access control; and reduce operational risk, fraud and cybercrime. RSA protects millions of users around the world and helps more than 90 percent of the Fortune 100 companies thrive and continuously adapt to transformational change.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005320/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
IAS Launches IAS Total TV Solutions Giving Marketers ‘Linear-like’ Transparency for Connected TV27.4.2026 14:30:00 CEST | Press release
‘IAS Total TV’ unlocks show, genre and rating transparency measurement across Disney, NBCUniversal, Paramount and Prime Video, plus multiple opted-in publishers using Publica enabling advertisers to enhance brand suitability while increasing campaign outcomes Integral Ad Science (IAS) today announced ‘IAS Total TV’, a new comprehensive suite of Connected TV (CTV) solutions designed specifically to bring ‘linear-like’ transparency to streaming TV. IAS Total TV can provide marketers with genre, rating, language, show and program-level data in aggregate from Disney, NBCUniversal, Paramount and Prime Video, in addition to multiple opted-in publishers using Publica. IAS Total TV integrates content insights, media quality, supply path and outcomes into a unified view within the IAS Signal user interface (UI). Advertisers can determine when and how they want their advertising to run alongside CTV content, ensuring brand-related and brand suitable environments. “As advertisers continue to doub
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 14:00:00 CEST | Press release
New Q1 2026 “Agentic Commerce Pulse” survey from Riskified reveals a growing trust gap in agent-driven commerce, as consumers embrace AI across the shopping journey but remain hesitant to hand over control amid concerns over fraud, security, and accountability Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-maki
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 14:00:00 CEST | Press release
90% of dealmakers expect cross-border M&A activity to increase over the next 12–24 months75% cite foreign direct investment screening as the biggest threat to deal completion88% report longer signing-to-close timelines than three years ago Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environ
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release
For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
